Top Markets
#1 Glidr Glidr +51.75%
#2 Akedo Akedo +51.75%
#3 DOVU DOVU +48.15%
#4 Black Phoenix Black Phoenix +34.08%
#5 Velvet Velvet +33.34%
#6 Cross Cross +29.27%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.47%
#8 OVERTAKE OVERTAKE +15.82%
#9 Bitway Bitway +15.10%
#10 QANplatform QANplatform +14.50%
Coin of the day
Glidr Glidr
Settings
Language
ENGLISH
Currency
USD
Theme
ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc.

ZVSA
Rank in Stocks #38793
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical... ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Share Price
$0.099
Market Cap
$801.50K
Change (1 day)
0.00%
Change (1 year)
-34.44%
Country
US
Trade ZyVersa Therapeutics, Inc. (ZVSA)

Category

Healthcare
Revenue for ZyVersa Therapeutics, Inc. (ZVSA)
Revenue in Aug 2026 TTM: 0
According to ZyVersa Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for ZyVersa Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE